Presenter of 1 Presentation
THE RELATIONSHIP BETWEEN CHRONIC COMPLICATIONS AND TIME IN RANGE IN PEOPLE WITH TYPE 1 DIABETES: A RETROSPECTIVE CROSS-SECTIONAL REAL-WORLD STUDY
Abstract
Background and Aims
Time in range (TIR; glucose of 70-180 mg/dL) overcomes some of the limitations of HbA1c in the individual assessment of glycemic control. This study evaluates whether TIR is associated with the presence of chronic complications in a real-world population of people with type 1 diabetes (T1D).
Methods
Sensor-measured TIR and the occurrence of microvascular (diabetic retinopathy [DR], diabetic nephropathy [DN], diabetic peripheral neuropathy [DPN]) and macrovascular complications in 812 people with T1D were analyzed cross-sectionally. Binary logistic regression was used to evaluate the contribution of TIR to the presence of chronic complications, after correction for sex, age, diabetes duration, BMI, blood pressure, lipid profile, smoking, lipid lowering and antihypertensive therapy.
Results
Mean TIR was 52.7 ± 15.2%. Overall, 46.1% had at least one microvascular complication (34.5% DR, 23.9% DN, 16% DPN) and 16.6% suffered from any macrovascular complication. The prevalence of at least one microvascular complication (p for trend <0.001), DR (p for trend <0.001) and DN (p for trend =0.036) decreased with increasing TIR quartiles (figure 1). The odds ratio of having at least one microvascular complication, DR, DN, DPN or any macrovascular complication per 1% increase in TIR was 0.969 (95%CI: 0.957-0.982, p<0.001), 0.959 (95%CI: 0.945-0.974, p<0.001), 0.981 (95%CI: 0.967-0.995, p=0.008), 0.980 (95%CI: 0.964-0.997, p=0.019) and 0.975 (95%CI: 0.958-0.992, p=0.005) respectively.
Conclusions
TIR is inversely associated with the presence of chronic diabetes complications. These data add validity to the use of TIR as key measure of glycemic control and endpoint of clinical trials, in addition to HbA1c.